HER2 + BREAST CANCER
Clinical trials for HER2 + BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2 + BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2 + BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug delivery methods tested for tough breast cancer
Disease control Not yet recruitingThis study is for people with HER2-positive advanced breast cancer. It tests a drug called SHR-A1811 given in different ways (like injection or infusion) to see which works best and is safest. About 60 adults who have had up to 2 prior treatments will take part. The goal is to sh…
Matched conditions: HER2 + BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
New study aims to spare women from chemo and major surgery for breast cancer
Disease control Not yet recruitingThis study tests a new approach for women with a common type of early breast cancer (HR+/HER2-). Instead of standard chemotherapy before surgery, some participants may receive a combination of hormone therapy and a targeted drug (abemaciclib) based on a gene test result from thei…
Matched conditions: HER2 + BREAST CANCER
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug duo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThis study tests whether a new combination of drugs (HLX87 and HLX22) works better than the standard treatment for people with HER2-positive early or locally advanced breast cancer. About 817 participants will receive the drugs before surgery to see if the cancer completely disap…
Matched conditions: HER2 + BREAST CANCER
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 14, 2026 12:03 UTC